R. Abdelnabi

Yeast-based production platform for potent and stable heavy chain-only antibodies

This paper presents a yeast-based platform for producing stable and potent heavy chain-only antibodies, demonstrating its effectiveness with an anti-SARS-CoV-2 example.

ACE2 mimetic antibody potently neutralizes all SARS-CoV-2 variants and fully protects in XBB.1.5 challenged monkeys

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike

The paper identifies ultrapotent SARS-CoV-2-neutralizing nanobodies that bind a conserved epitope on the spike protein, showing therapeutic efficacy in hamsters.

Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infection

This study examines the genetic effects of effective and suboptimal dosing of mutagenic drugs on SARS-CoV-2 in hamsters, finding dose-dependent mutational load and no drug resistance.

Combination of the parent analogue of Remdesivir (GS-441524) and Molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters

This study shows that combining GS-441524 and molnupiravir significantly reduces SARS-CoV-2 viral load in infected Syrian hamsters.

Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in Syrian hamsters

This study shows that nirmatrelvir-resistant SARS-CoV-2 variants replicate and transmit efficiently in Syrian hamsters, highlighting the need for combination therapies to prevent resistance spread.

A SCID mouse model to evaluate the efficacy of antivirals against SARS-CoV-2 infection

This paper establishes a SCID mouse model infected with the SARS-CoV-2 beta B.1.351 variant to evaluate antiviral efficacy, showing significant reduction in viral load with Molnupiravir and Nirmatrelvir.

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

This study shows that hybrid immunity and vaccine boosters provide potent neutralizing activity against Omicron BA.1 and BA.2, while breakthrough infections induce nasal mucosal neutralization and identify an ultrapotent pan-variant antibody.

ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies

The paper identifies monoclonal antibodies that neutralize multiple coronaviruses by targeting the fusion peptide, which becomes exposed upon ACE2 engagement.

SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique Spike binding properties

This paper identifies a potent human monoclonal antibody, P2G3, that neutralizes multiple SARS-CoV-2 variants including Omicron, and demonstrates its protective efficacy in a monkey model.

Ivermectin does not protect against SARS-CoV-2 infection in the Syrian hamster model

This study shows that Ivermectin does not reduce SARS-CoV-2 lung viral load or improve lung pathology in Syrian hamsters and does not enhance Molnupiravir's effect.

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters

This study shows that the omicron SARS-CoV-2 variant infects Syrian hamsters with significantly lower viral loads in the lungs compared to the D614G strain, with no detectable infectious virus.

Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model

The paper identifies potent anti-SARS-CoV-2 mAbs that cure infection in hamsters and demonstrates gene-based delivery for in vivo protection against variants.

Updated vaccine protects from infection with SARS-CoV-2 variants, prevents transmission and is immunogenic against Omicron in hamsters

This study shows an updated vaccine candidate provides full protection against multiple SARS-CoV-2 variants, prevents transmission, and induces neutralizing antibodies against Omicron in hamsters.

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern

PF-07321332, an oral protease inhibitor, effectively protects Syrian hamsters against SARS-CoV-2 variants of concern, including beta and delta, by preventing infection and transmission.

Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry

This study identifies a broadly neutralizing antibody against sarbecoviruses that targets the ACE2 binding site and shows high resistance to escape mutations.

A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery

This paper identifies a human antibody that broadly neutralizes betacoronaviruses by targeting the stem helix, showing protection against SARS-CoV-2 and potential for vaccine design.

Perturbation of alphavirus and flavivirus infectivity by components of the bacterial cell wall

This study shows that bacterial cell wall components reduce alphavirus and flavivirus infectivity by directly interacting with viral particles in vitro.

Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody

This paper identifies a human monoclonal antibody that broadly neutralizes SARS-CoV-2 variants and zoonotic sarbecoviruses by targeting a conserved epitope on the spike protein.

Comparative infectivity and pathogenesis of emerging SARS-CoV-2 variants in Syrian hamsters

This study compares the infectivity and pathogenicity of SARS-CoV-2 variants B.1.1.7 and B.1.351 to early 2020 strains in Syrian hamsters, finding similar disease outcomes but stronger proinflammatory cytokine elevation in B.1.1.7 infections.

ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model

This study evaluates ALG-097111, a selective SARS-CoV-2 3CLpro inhibitor, showing potent in vitro activity and significant in vivo antiviral effects in Syrian hamsters.

Nelfinavir markedly improves lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect

Nelfinavir reduces SARS-CoV-2-induced lung pathology in Syrian hamsters without affecting viral RNA or infectious titers.

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

The paper identifies a conserved antigenic supersite on the SARS-CoV-2 N-terminal domain recognized by neutralizing antibodies and shows its vulnerability to mutations in variants.

The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

This study shows that combining Molnupiravir and Favipiravir significantly enhances antiviral efficacy against SARS-CoV-2 in hamsters, reducing viral titers by 4.5 log10 and eliminating detectable virus in 60% of treated animals.

Pan-viral protection against arboviruses by targeting inoculation site-based skin macrophages

The paper shows that activating innate immune responses at the mosquito bite site, specifically targeting skin-resident macrophages, can inhibit systemic arbovirus dissemination and improve clinical outcomes.